Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer
Interventions: Ipilimumab, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 42
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 36 more

Conditions: Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Interventions: data collection; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Prostate Cancer
Interventions: Standard of Care; Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer
Interventions: Navigation; Other
Lead sponsor: Queen's Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 628 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Kaunakakai, Hawaii

Conditions: Adenocarcinoma of the Prostate
Interventions: NanoPac®; Drug
Lead sponsor: NanOlogy, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Castration-resistant Prostate Cancer, Androgen Deprivation Therapy
Interventions: Home-based exercise; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Prostate Cancer
Interventions: Docetaxel; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Casodex, Axumin, Salvage Radiation, Axumin; Drug · Radiation
Lead sponsor: Cancer Center of Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Irvine, California

Conditions: Prostate Cancer
Interventions: Uronav guided biopsy, Magnetic resonance imaging; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Focal Therapy; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Prostate Cancer
Interventions: vitamin D3, Placebo daily for one year; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years to 85 Years · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Prostate Cancer
Interventions: 18F-DCFPyL Injection; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: Carboplatin, 177Lu-PSMA-617; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Prostatic Neoplasms, Prostate Cancer, Recurrence
Interventions: [18F]CTT1057, [68Ga]Ga-PSMA-11; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
Interventions: Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Detroit, Michigan • Farmington Hills, Michigan • New Brunswick, New Jersey + 1 more

Conditions: Prostate Cancer
Interventions: Cu-NU101; Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Newport Beach, California • St Louis, Missouri

Conditions: Prostate Cancer
Interventions: GTx-758; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: San Bernardino, California • Jeffersonville, Indiana • Albuquerque, New Mexico + 4 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000; Drug · Radiation · Device
Lead sponsor: Parker Institute for Cancer Immunotherapy; Other
Eligibility: 18 Years and older · Male only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • New York, New York + 2 more

Conditions: Prostate Cancer
Interventions: PLX3397; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Bony Metastases From Castrate Refractory Prostate Cancer
Interventions: Radium-223 dichloride; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Genetic Counseling, Genetic Testing, Laboratory Biomarker Analysis, Questionnaire; Procedure · Other · Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Darolutamide(Nubeqa, BAY1841788); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 24
States / cities: Homewood, Alabama • Tucson, Arizona • San Diego, California + 21 more

Conditions: Prostate Cancer
Interventions: Ursolic Acid, Curcumin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Los Angeles, California • Pasadena, California

Search by objective public record fields.

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Optional Sub-study to Intraoperative Imaging With ICG Registry

African Cancer Genome: GMD

Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer

A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy

Defining Recurrent Disease With Axumin™

Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning

Focal Therapy for Localized Prostate Cancer

Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Study of Diagnostic Performance of [18F]CTT1057 in BCR

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

Genetic Testing for Men With Metastatic Prostate Cancer

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients